Dr Xin Jiang
Senior Research Fellow

Dr Xin Jiang

Science
School of Biotech & Biomolecular Science

Dr. Xin Jiang is a biochemist/structural biologist working on the mechanism investigation of membrane proteins. Mentored by Prof. Yigong Shi, Xin was awarded his Ph.D. degree in 2017 from Tsinghua University, where he received systematic training in protein expression, purification, engineering, and characterization. He joined Prof. Nieng Yan's lab at Princeton University in 2018 for his postdoctoral training. During his postdoctoral period, Xin systematically revealed the molecular mechanism underlying the glucose and lactate transport cycle in human and Plasmodium. Later, Dr. Xin Jiang joined the BABS of UNSW in 2019 as a senior research fellow. 

  • Journal articles | 2022
    2022, 'An overview of the Plasmodium falciparum hexose transporter and its therapeutic interventions', Proteins: Structure, Function and Bioinformatics, 90, pp. 1766 - 1778, http://dx.doi.org/10.1002/prot.26351
    Journal articles | 2022
    2022, 'Molecular basis for inhibiting human glucose transporters by exofacial inhibitors', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-30326-3
    Journal articles | 2022
    2022, 'Structural aspects of the glucose and monocarboxylate transporters involved in the Warburg effect', IUBMB Life, 74, pp. 1180 - 1199, http://dx.doi.org/10.1002/iub.2668
    Journal articles | 2021
    2021, 'Orthosteric–allosteric dual inhibitors of PfHT1 as selective antimalarial agents', Proceedings of the National Academy of Sciences of the United States of America, 118, http://dx.doi.org/10.1073/pnas.2017749118
    Journal articles | 2021
    2021, 'Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates', Cell, 184, pp. 370 - 383.e13, http://dx.doi.org/10.1016/j.cell.2020.11.043
    Journal articles | 2021
    2021, 'Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism', PLoS Biology, 19, http://dx.doi.org/10.1371/journal.pbio.3001386
    Journal articles | 2020
    2020, 'Regulation of aerobic glycolysis to decelerate tumor proliferation by small molecule inhibitors targeting glucose transporters', Protein and Cell, 11, pp. 446 - 451, http://dx.doi.org/10.1007/s13238-020-00725-7
    Journal articles | 2020
    2020, 'Structural Basis for Blocking Sugar Uptake into the Malaria Parasite Plasmodium falciparum', Cell, 183, pp. 258 - 268.e12, http://dx.doi.org/10.1016/j.cell.2020.08.015
    Journal articles | 2019
    2019, 'Engineered XylE as a tool for mechanistic investigation and ligand discovery of the glucose transporters GLUTs', Cell Discov, 5, pp. 14 - 14, http://dx.doi.org/10.1038/s41421-019-0082-1
    Journal articles | 2017
    2017, 'MiR-30a targets IL-1α and regulates islet functions as an inflammation buffer and response factor', Scientific Reports, 7, http://dx.doi.org/10.1038/s41598-017-05560-1
    Journal articles | 2017
    2017, 'Molecular determinants for the thermodynamic and functional divergence of uniporter GLUT1 and proton symporter XylE', PLoS Comput. Biol., 13, pp. e1005603 - e1005603, http://dx.doi.org/10.1371/journal.pcbi.1005603
    Journal articles | 2016
    2016, 'Berberine enhances antidiabetic effects and attenuates untoward effects of canagliflozin in streptozotocin-induced diabetic mice', Chinese Journal of Natural Medicines, 14, pp. 518 - 526, http://dx.doi.org/10.1016/S1875-5364(16)30061-9
    Journal articles | 2016
    2016, 'Crystal structure of a LacY-nanobody complex in a periplasmic-open conformation', Proc. Natl. Acad. Sci. U.S.A., 113, pp. 12420 - 12425, http://dx.doi.org/10.1073/pnas.1615414113
    Journal articles | 2016
    2016, 'Dysregulated serum miRNA profile and promising biomarkers in dengue-infected patients', International Journal of Medical Sciences, 13, pp. 195 - 205, http://dx.doi.org/10.7150/ijms.13996
    Journal articles | 2016
    2016, 'Novel synergic antidiabetic effects of Astragalus polysaccharides combined with Crataegus flavonoids via improvement of islet function and liver metabolism', Molecular Medicine Reports, 13, pp. 4737 - 4744, http://dx.doi.org/10.3892/mmr.2016.5140
    Journal articles | 2015
    2015, 'Dysregulated serum microRNA expression profile and potential biomarkers in hepatitis C virus-infected patients', International Journal of Medical Sciences, 12, pp. 590 - 598, http://dx.doi.org/10.7150/ijms.11525
    Journal articles | 2015
    2015, 'Molecular basis of ligand recognition and transport by glucose transporters', Nature, 526, pp. 391 - 396, http://dx.doi.org/10.1038/nature14655
    Journal articles | 2013
    2013, 'Analysis of the selectivity filter of the voltage-gated sodium channel Na(v)Rh', Cell Res., 23, pp. 409 - 422, http://dx.doi.org/10.1038/cr.2012.173
  • Preprints | 2022
    2022, Comprehensive preclinical evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9ORF72 disease, , http://dx.doi.org/10.1101/2022.01.13.475329
    Preprints | 2021
    2021, Nanocrown electrodes for reliable and robust intracellular recording of cardiomyocytes and cardiotoxicity screening, , http://dx.doi.org/10.1101/2021.09.28.462181
    Preprints | 2021
    2021, Patient-Derived Three-Dimensional Cortical Neurospheres to Model Parkinson’s Disease, , http://dx.doi.org/10.1101/2021.08.21.457201
    Preprints | 2020
    2020, Orthosteric-allosteric dual inhibitors of PfHT1 as selective anti-malarial agents, , http://dx.doi.org/10.1101/2020.08.25.260232

We are interested in understanding the molecular mechanism of membrane proteins and their therapeutic application. Specifically, we work on two different aspects of research fields.

The first aspect of our research interest is to reveal the function and mechanism of the plasmodium membrane proteins, followed by drug development. For instance, the plasmodium transporters play critical roles in absorbing nutrition, extruding metabolic waste, and maintaining osmotic balance. Inhibition of these membrane transport proteins can efficiently hamper the proliferation of plasmodium, which provides a novel path to cure malaria. Importantly, current clinical antimalarial agents are not targeting the membrane transporters. Therefore, the novel transporter inhibitors are promising medicines to fight against the multidrug-resistant plasmodium that increasingly threatens the campaign for malaria elimination.

The other research topic is in collaboration with senior lipid researchers in BABS. Currently, we try to understand the molecular mechanisms of several membrane proteins that play important roles in lipid and cholesterol biogenesis.